Occurrence of CSF3R mutations in patients with CN and development of secondary malignancies
| Patient group . | No CSF3R nonsense mutation, no. (%) . | CSF3R nonsense mutation, no. (%) . | Total no. . |
|---|---|---|---|
| CN without Mo7/MDS/leukemia | 82 (66) | 43 (34) | 125 |
| CN with Mo7/MDS/leukemia | 5 (22) | 18 (78) | 23 |
| CN/Mo7 | 0 | 2 | 2 |
| CN/MDS | 1 | 4 | 5 |
| CN/AML | 4 | 9 | 13 |
| CN/ALL | 0 | 2 | 2 |
| CN/CMML | 0 | 1 | 1 |
| Total CN | 87 (59) | 61 (41) | 148 |
| Patient group . | No CSF3R nonsense mutation, no. (%) . | CSF3R nonsense mutation, no. (%) . | Total no. . |
|---|---|---|---|
| CN without Mo7/MDS/leukemia | 82 (66) | 43 (34) | 125 |
| CN with Mo7/MDS/leukemia | 5 (22) | 18 (78) | 23 |
| CN/Mo7 | 0 | 2 | 2 |
| CN/MDS | 1 | 4 | 5 |
| CN/AML | 4 | 9 | 13 |
| CN/ALL | 0 | 2 | 2 |
| CN/CMML | 0 | 1 | 1 |
| Total CN | 87 (59) | 61 (41) | 148 |
The correlation between occurrence of CSF3R mutations and the development of secondary malignancies was highly significant using the Pearson chi-square test (P = 8.6 × 10−5).
CN indicates congenital neutropenia; Mo7, monosomy 7; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CMML, chronic myelomonocytic leukemia.